Telix Pharmaceuticals (TLX) Non-Current Assets (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Non-Current Assets of -$330.3 million for Q4 2025, down 184.48% year-over-year from $391.0 million in Q4 2024, and down 184.48% quarter-over-quarter from $391.0 million in Q4 2024.
Telix Pharmaceuticals (TLX) Non-Current Assets (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Non-Current Assets for 3 consecutive years, with -$330.3 million the latest figure, recorded in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - | -330.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -330.28 Mn |
| Dec 31, 2024 | 390.98 Mn |
| Dec 31, 2023 | 112.92 Mn |